Growth and Demand of Bioburden Testing in Biotechnology and Pharmaceutical Industry

The bioburden testing market is witnessing growth due to factors such as growth in the medical devices, pharmaceutical, and biotechnology industries; rising safety concerns related to food and beverage products; and the increasing number of product recalls due to microbial contamination are expected to drive the growth of this market during the forecast period.

Bioburden Testing Market Dynamics: Impact Analysis

1. Geographical Snapshot of the Bioburden Testing Market
2. Growth Opportunities in Emerging Economies
3. Growth in the Medical Devices, Pharmaceutical, and Biotechnology Sector
4. Safety Concerns Related to Food and Beverage Products
5. Increasing Food Imports Into the US

The bioburden testing market to grow from USD 1.10 billion by 2023 from USD 0.61 billion in 2018, at a Compound Annual Growth Rate (CAGR) of 12.4% Key Questions Addressed in The Report: 1. Who are the top 10 players operating in the global Bioburden Testing market?
2. What are the drivers, restraints, opportunities, and challenges in the Bioburden Testing Industry?
3. What are the opportunities for stakeholders and provide details of the competitive landscape for key players?
4. What will be growth of Bioburden Testing in North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa?

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=17983056

Bioburden Testing Application: Raw Materials Testing Based on the application, the bioburden testing market is segmented into raw materials testing, medical devices testing, in-process material testing, sterilization validation testing, and equipment cleaning validation. In 2018, the raw materials testing segment is expected to grow at the highest CAGR during the forecast period. Growth in this segment is likely to be driven by the rising quality standards to ensure safety of finished products.

Products of Bioburden Testing: Consumables Segment Based on product, the bioburden testing market is segmented consumables and instruments. Consumables segment further segmented into culture media, reagents and kits, and other consumables. Instruments segment further categorised as automated microbial identification system, PCR, microscope, and other instruments. In 2018, the consumables segment is expected to account for the largest share of the bioburden testing market. The large share of this segment majorly attributed to the requirement of repeat purchase of kits and reagents, unlike instruments which are considered as a one-time investment.

Regional Growth Analysis: North America and Europe to Dominate The Industry:

The market is dominated by North America, followed by Europe, Asia, and RoW. North America is expected to continue to dominate this market in the forecast period. The large size of the North American biotechnology industry will aid in the growth of the bioburden testing market in this region. However, Asia is expected to grow at the highest CAGR during the forecast period. Strong investments and rapid growth in the pharmaceutical and biotechnology industries will drive the growth of the bioburden testing market in this region.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=17983056

Key Players: The bioburden testing market is competitive in nature, with several big as well as emerging players. Prominent players in this market include Charles River (US), Merck KGaA (Germany), SGS SA (Switzerland), WuXi AppTec (China), Becton, Dickinson, and Company (US), NAMSA (US), Nelson Laboratories, LLC (US), Thermo Fisher Scientific, Inc. (US), Biomérieux SA (France), and Pacific BioLlabs (US)